CagriSema
cagrilintide/semaglutide
FILED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Peak Sales Est$15000M
Formulations[]
Mechanism: GLP-1/Amylin dual agonist
Expert: Dual agonist targeting both GLP-1 and amylin receptors, providing synergistic effects on satiety, gastric emptying, and glucose homeostasis through complementary central and peripheral mechanisms.
Everyday: Combines two hormones that work together to reduce appetite and blood sugar more effectively than either alone.
Targets: ["GLP-1","AMYLIN"]
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| Obesity | FILED | REDEFINE 1-3 | [{"stage":"FILED","region":"US"}] |
| Type 2 Diabetes | PHASE3 | REIMAGINE 1-5 | [] |
Clinical Studies (1)
Primary EP: [{"id":"ep1","name":">= 25% body weight loss at Week 72","type":"PRIMARY","unit":"%","results":[],"timepoint":"Week 72","description":"Responder rate measuring percentage of patients who achieve at le
Upcoming Catalysts (4)
CagriSema - T2D - Ph3 - Data (REIMAGINE 3/4/5)
H2 2026
CagriSema vs Zepbound - Obesity - Ph3 - Topline (REDEFINE-4)
H2 2026
CagriSema - Obesity - FDA PDUFA
Q4 2026
CagriSema - Obesity CVOT - Ph3 - Updates (REDEFINE 3)
2026
Notes
Fixed-dose combination: cagrilintide 2.4mg + semaglutide 2.4mg. NDA filed Dec 2025 for obesity. Phase 3 REIMAGINE program ongoing for T2D.
Data from Supabase · Updated 2026-03-24